The filing is a routine RSU-cover-to-tax sale by an officer with no discretionary signal. Monitor for any subsequent Form 4 filings to confirm execution, but no trading action is warranted based on this notice alone.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 14 $25.70entry
- T+1 · 3mo ago +1.75%α +2.22% · $26.15
- T+5 · 3mo ago +1.56%α +2.92% · $26.10
- T+20 · 2mo ago −27.94%α −25.95% · $18.52
- T+60 · 8d ago −26.96%α −24.16% · $18.77
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Erick Lucera, an officer of Dyne Therapeutics, filed a Form 144 on August 13, 2026, indicating intent to sell 1,797 shares of common stock with an approximate market value of $47,226. The shares were acquired via restricted stock unit vesting on August 12, 2026, and the sale is for equity compensation-related tax obligations. Given the small size relative to the company's $4.9B market cap and the routine nature of RSU-based sales, this filing is neutral.
Key Facts
- Officer Erick Lucera filed Form 144 to sell 1,797 shares of Dyne Therapeutics common stock.
- Estimated sale value is approximately $47,226 based on filing date.
- Shares were acquired via restricted stock unit vesting on August 12, 2026.
- Sale is for equity compensation-related purposes, not a discretionary open-market exit.
- The proposed sale represents a negligible fraction of the company's $4.9B market capitalization.
Financial Impact
Proposed sale of 1,797 shares worth ~$47,226, immaterial relative to $4.9B market cap.
Risk Factors
- Form 144 is an intent to sell, the sale may not be executed.
- No material risk to the company or stock from this de minimis insider sale.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001972481-26-000259 |
| Document: 0001972481-26-000259-index.html | 0001972481-26-000259 |
| Document: 0001972481-26-000259.txt | 0001972481-26-000259 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers